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Abstract
Objective: This study aimed external validation of a formerly developed prediction model identifying children at risk for
hearing loss after bacterial meningitis (BM). Independent risk factors included in the model are: duration of symptoms prior
to admission, petechiae, cerebral spinal fluid (CSF) glucose level, Streptococcus pneumoniae and ataxia. Validation helps to
evaluate whether the model has potential in clinical practice.
Study design: 116 Dutch school-age BM survivors were included in the validation cohort and screened for sensorineural
hearing loss (.25 dB). Risk factors were obtained from medical records. The model was applied to the validation cohort and
its performance was compared with the development cohort. Validation was performed by application of the model on the
validation cohort and by assessment of discrimination and goodness of fit. Calibration was evaluated by testing deviations
in intercept and slope. Multiple imputation techniques were used to deal with missing values.
Results: Risk factors were distributed equally between both cohorts. Discriminative ability (Area Under the Curve, AUC) of
the model was 0.84 in the development and 0.78 in the validation cohort. Hosmer-Lemeshow test for goodness of fit was
not significant in the validation cohort, implying good fit concerning the similarity of expected and observed cases. There
were no significant differences in calibration slope and intercept. Sensitivity and negative predicted value were high, while
specificity and positive predicted value were low which is comparable with findings in the development cohort.
Conclusions: Performance of the model remained good in the validation cohort. This prediction model might be used as a
screening tool and can help to identify those children that need special attention and a long follow-up period or more
frequent auditory testing.
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Introduction
Due to successful vaccination programs, and to spontaneous
decline in Neisseria meningitidis serogroup B infections, the incidence
of bacterial meningitis (BM) in childhood is decreasing in the
Western world. Still, BM ranks among the top ten causes of death
in children younger than 14 years in high-income countries.
Further, developing countries account for 98% of the estimated
5.6 million disability-adjusted life years attributed to meningitis
globally [1,2]. Sensorineural hearing loss is the most common
severe consequence of BM, with an incidence in children of 7–
31% [3,4,5,6,7,8,9]. Hearing loss after BM is probably multicaus-
al. Bacterial labyrinthitis due to dissemination of the infection from
the subarachnoid space in combination with toxic or serous
labyrinthitis, direct nerve fiber damage and secondary ischemic
damage are thought to be part of the mechanism [10].
Especially in (young) children even mild impairment in hearing
abilities may impair auditory, linguistic, communication and
learning skills. Early identification of hearing loss is indispensable
for effective treatment resulting in the acquisition of normal
linguistic development [11,12]. Further, cochlear ossification may
complicate cochlear implantation making early diagnosis even
more essential. [13,14].
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The actual incidence of post-meningitis hearing loss is probably
underestimated because audiometric testing is only performed in
clinical suspected cases. Many cases are late or never diagnosed
[9]. For that reason, routine hearing evaluation is recommended
in the standard follow-up program of childhood BM aiming to
achieve more timely intervention [8,14].
To support the recognition of patients at high risk for hearing
loss after BM, Koomen et al. developed a clinical prediction rule
(figure 1) [6]. Clinical prediction rules are (regression) models that
use three or more variables from patient history, clinical course or
diagnostic tests to calculate a probability of an outcome measure.
These rules are potentially strong tools that are currently used in
clinical decision-making [15]. The model constructed by Koomen
et al. included the following independent predictors for hearing
loss: duration of symptoms prior to admission, absence of
petechiae, cerebral spinal fluid (CSF) glucose level, Streptococcus
pneumoniae as causative pathogen and ataxia.
In general a prediction model does not perform well in a
different cohort than the one it was constructed in. For that reason
external validation in an independent cohort is essential before
implementation in practice [16,17,18]. The aim of this study was
to externally validate the existing model for hearing loss after
childhood BM in a validation cohort of Dutch school-age BM
survivors in order to evaluate the potential for usage in clinical
practice.
Methods
The study was approved by the medical ethics committee of the
VU University Medical Center in Amsterdam. Written informed
consent was obtained from the parents or guardians of all children
and from the children themselves if they were at least 12 years of
age.
Development Cohort
The construction of the prediction rule was described in the
original publication by Koomen et al. [6]. Files of the Netherlands
Reference Laboratory for BM (NRLBM) were searched for
children born between January 1986 and December 1994 who
survived BM between January 1990 and December 1995. The
NRLBM receives approximately 90% of the isolates of Dutch
meningitis patients [19]. The diagnosis BM was based on the
isolation of bacteria in the CSF. Exclusion criteria included a
complex onset of meningitis (defined as: meningitis secondary to
immunodeficiency states, CNS surgery, cranial trauma, CSF shunt
infections of relapsing meningitis), pre-existent cognitive or
behavioral problems, and diseases developed after BM, which
could have caused cognitive or behavioral problems. These last 2
exclusion criteria were used while the cohort was also constructed
for a study on academic or behavioral problems after BM [20].
Sixteen hundred and five children were eligible for inclusion
and their pediatricians were approached to send the parents a
letter requesting participation. Six hundred and twenty-eight
children were included, and their medical records were investi-
gated for risk factors and for perceptive hearing loss of .25 dB.
Hearing loss was found in forty-three children (7%) and by
reviewing medical records; information was collected on all
potential risk factors for this hearing loss. Predictors univariably
associated with the outcome (p#0.10) were included and a
prediction model was developed using multivariable logistic
regression. Five risk factors for hearing loss were found to be
independent determinants: duration of symptoms prior to
admission longer than two days, the absence of petechiae, CSF
glucose level #0.6 mmol/L, S. pneumoniae as causative pathogen
and the presence of ataxia during the illness. After internal
validation using bootstrapping techniques and shrinkage of
regression coefficients this model was transformed into a clinical
prediction rule as presented in figure 1. The scores and the
matching probability of hearing loss were visually presented in a
nomogram for use in clinical practice. [6].
Validation Cohort
In 2005, the files of the NRLBM were searched again for Dutch
children born between January 1993 and December 1999 who
suffered from non-Haemophilus influenzae type b (Hib) BM between
January 1997 and December 2001. The exclusion criteria were
identical to those used in the original study [6]. One thousand and
thirty-six children were eligible for inclusion, and the pediatricians
were requested to send the parents (or guardians) an invitation
letter to participate in the study. After informed consent the
parents were sent screening questionnaires regarding health,
learning and behavior. Three hundred and fifty eight children
were included in the cohort used for validation of this model.
Parallel to the approach used in the development study of
Koomen et al. in which a prediction rule for academic and
behavioral problems after BM was constructed, a nested cohort
approach was used [20]. In this design only a subset of cases and
controls are selected for further analysis, which decreases the
necessary time and financial resources resulting in an improved
efficiency [20,21].
In the total cohort of 358 children a nested cohort of 160
children were randomly selected and invited to visit our
department for academic and neuropsychological testing and for
the completion of questionnaires regarding behavior and health.
Forty-four of the invited children did not participate in this part of
the study.
Again, the outcome measure ‘‘hearing loss’’ was defined as a
unilateral or bilateral perceptive loss of .25 dB and was based on
findings in these records and on parental information provided in
the questionnaires about the children’s health (Dutch versions of
the Child Health Questionnaire (CHQ) and the Health Utilities
Index (HUI) mark 2&3) [22,23]. Information on the risk factors for
hearing loss was also collected by reviewing medical records of the
pediatrician and the otolaryngologist after permission from the
parents. Conductive hearing loss was not included. Finally,
Figure 1. clinical prediction rule for the prediction of hearing loss after childhood BM, as presented by Koomen et al.
doi:10.1371/journal.pone.0058707.g001
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information about hearing loss was retrieved from 116 children.
Figure 2 presents a flow chart of patient inclusion.
The risk factors evaluated for this study were the five
aforementioned independent predictors included in the original
model.
Data analysis. Univariate comparison of the distribution of
patient characteristics and clinical data in the development and the
validation cohort was performed by independent sample t-tests for
continuous and x2-tests for nominal data. Fisher’s Exact test was
used if the data did not meet the criteria for a x2-test. Statistical
significance was considered with 2-tailed p-values of #0.05.
Missing Data
In both the development and the validation cohort multiple
imputation techniques were used for substitution of missing
variables. In the development cohort a maximum of 20% of the
data was missing per variable [6]. In the validation cohort no more
than 5% of the data was missing per variable, resulting in 9.5%
missing cases for the whole model. Imputation was repeated five
times, resulting in five different datasets [24,25,26].
External Validation
For external validation the discriminative ability of the model in
both cohorts was compared. In all sets the model with the original
Figure 2. Flow chart of patient inclusion.
doi:10.1371/journal.pone.0058707.g002
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regression coefficients was applied on the data of each individual
child. Receiver operating characteristic (ROC) curves of all
imputated datasets were constructed for these results predicting
the outcome measure ‘‘hearing loss’’. An average area under the
curve (AUC) was calculated and compared with the average AUC
of the ROC curves of the development cohort. The fit of the
model in the validation cohort was tested with the Hosmer-
Lemeshow test for goodness of fit. For this test the patients were
grouped by decile of predicted probability and differences between
expected and observed outcome in the ten groups were tested
using x2-tests. The five results of these x2-tests of the imputated
datasets were pooled [27].
The intercept in a logistic regression model results in equal
averages of the predicted probabilities and the outcomes when the
model is applied in the validation cohort (‘‘calibration in the
large’’). The slope reflects that the regression coefficients are
correctly estimated and that they yield the correct predictions in
the validation cohort. We also assessed more specifically whether
calibration was successful by separately testing deviations in the
intercept and calibration slope when the model was applied in the
validation cohort [27].
For each child in the validation cohort the individual risk score
was calculated. The distribution of the number of subjects across
categories according to these scores were compared between the
development and the validation cohort. Positive and negative
predictive value, sensitivity and specificity were calculated for
different cut-off points and were compared for their clinical value
with those composed with the original prediction model.
All data was analyzed using SPSS Statistics 18.0 (IBM
Corporation, Somers, NY) and R (The R Project for Statistical
Computing).
Results
Table 1 presents the distribution of the patient characteristics,
independent predictors and the outcome measure ‘‘hearing loss’’
in the development and the validation cohort. Differences in
distribution of characteristics between the two cohorts were
observed for the duration of symptoms before admission,
consciousness, presentation of the child with meningeal irritation
at admission, (duration of) dexamethasone prescription, number of
children mechanically ventilated, duration of hospitalization,
duration of anti-epileptic therapy and the number of children
with focal neurological deficits. There were no significant
differences in the distributions of the five predictors of the
prediction rule. The incidence of hearing loss was 6.8% in the
development cohort and 12.1% in the validation cohort.
External Validation of the Prediction Rule
The average AUC of the ROC curves of the validation cohort
was 0.78 (95% CI 0.64–0.92). In the development cohort, the
reported AUC was 0.84 (95% CI 0.78–0.91) [6]. The pooled result
of the Hosmer-Lemeshow test for goodness of fit of the five
datasets was not significant (p-value 0.10), indicating good fit of the
model in the validation cohort concerning the similarity of
expected and observed cases of hearing loss. When the original
model was applied in the validation cohort there was no significant
deviation in intercept (p=0.07–0.11) and calibration slope
(p=0.14–0.34).
Comparison of the Distribution of Risk Score Categories
Table 2 shows the numbers of subjects across categories of the
score for both the development and the validation cohort.
Children without hearing loss had an average risk score of 19.6
and children with hearing 45.3. In both cohorts approximately
40% of children without hearing loss score zero points, while only
1 child of all children with hearing loss has a score of 0. While
most of the children with hearing loss had a higher score, children
without hearing loss were in the groups with high scores as well.
Table 3 presents positive and negative predictive value, sensitivity
and specificity for the different cut-off points. Using a cut-off point
of zero, the sensitivity is 100% while at a score of 1–25 the
negative predicted value is 97.8%. At a maximum score on the risk
score the specificity is 96.1%, but decreases rapidly at a lower
score. The positive predictive value is low (60%). The conclusion
of these tables is that sensitivity and negative predictive value are
good, but specificity and positive predictive value are poor.
Discussion
In this study, the prediction model for hearing loss after
childhood BM was validated successfully in a new independent
cohort of school-age children. This is the first validated model for
the identification of children at high risk for hearing loss after BM.
Our recommendation is that at least the patients who are positive
at one or more risk score should achieve timely and frequent
hearing evaluation. It is not a replacement for standard hearing
tests, but an addition to these tests, to estimate the risk for hearing
loss in an early stage of disease.
Despite increasing awareness and recommendation of routine
hearing evaluation in the standard follow-up of childhood BM, the
amount of children whom hearing is not tested or hearing loss is
even missed could be up to 25–30% [6,14]. Relatively little is
known about the clinical course of hearing loss after BM. It is not
always noticeable or present directly after the infection and
fluctuation and deterioration of hearing later in time might occur
[28,29,30]. Modern follow-up protocols therefore include a
prolonged period of hearing loss evaluation. The only current
treatment option in complete and profound hearing loss is
cochlear implantation, which may only be possible in a critical
period. A good opportunity for hearing restoration could
disappear within weeks since labyrinthitis ossificans makes
implantation extremely difficult or even impossible [14,31]. This
prediction model can be used as a screening tool and can help to
identify those children that need special attention and a long
follow-up period or more frequent auditory testing even when the
first test is negative.
For clinical practice the optimal cut-off point of the risk score
has to be defined. Conform Koomen et al. we state that hearing
loss should not be missed at all and therefore propose a low cut-off
value of zero points [6]. In this study it was confirmed that this is
the optimal cut-off point. The risk score reaches excellent
sensitivity and negative predictive value at this cut-off point.
Unfortunately, as one increased the sensitivity of a rule, its
specificity tends to decrease (and vice versa). In clinical practice,
this indicates that our prediction rule has to be used to select the
children at high risk, accepting the fact that a relatively high
number of children without hearing impairment will be selected as
well. Although with a low cut-off point sensitivity is high, in the
validation cohort one child with a score of zero points did have
hearing loss, while in the construction cohort no case was missed.
We conclude that at least those patients who are positive at one or
more factor score should achieve timely and frequent hearing
evaluation. In the lower risk group, hearing must be evaluated as
well, but it may be considered to perform auditory tests less
frequently of for a shorter time period. This may improve the
balance between costs and benefit. It can create awareness of the
Successful Validation of BM Hearing Loss Model
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Table 1. Patient characteristics of the development and validation cohort.
Characteristics
Validation cohort
(n=116)
Development cohort
(n =628)
p-valuef
(development vs
validation cohort)
Noa Noa
Age at infection (years)b 116 2.5 (1.8) 628 2.4 (2.0) 0.58
Male genderc 116 57 (49.1%) 628 356 (56.7% 0.13
Patient history and physical examination at admission
Duration of symptoms prior to admission (days)b 113 2.4 (1.4) 621 1.9 (1.8) 0.001
Duration of symptoms .2 daysc 113 36 (31.9%) 621 146 (23.5%) 0.059
Seizures prior to admissionc 116 8 (6.9%) 628 57 (9.1%) 0.45
Seizures ad admissionc 116 4 (3.4%) 628 59 (9.4%) 0.035
Decreased consciousnessc 106 53 (50.0%) 590 401 (68.0%) ,0.001
Rectal temperature (uC)b 100 39.1 (1.2) 583 39.1 (1.0) 0.64
Rectal temperature $38uCc 112 94 (83.9%) 583 502 (86.1%) 0.55
Meningeal irritationc 109 78 (71.6%) 628 511 (81.4%) 0.018
Petechiaec 115 65 (56.5%) 618 336 (54.4%) 0.67
Focal neurological deficitsc, d 115 6 (5.2%) 628 58 (9.2%) 0.16
Middle ear infectionc 93 13 (14.0%) 514 48 (9.3%) 0.17
Laboratory tests
CSF leukocyte count (/uL)b 111 3827 (6778) 548 3736 (6719) 0.90
CSF glucose (mmol/l)b 110 2.2 (1.9) 543 2.2 (1.8) 0.94
CSF glucose #0.6 mmol/lc 110 33 (30.0%) 543 165 (30.4%) 0.94
CSF protein level (g/l)b 104 1.8 (1.5) 508 1.8 (1.7) 0.89
Causative pathogen in CSF: (total) 116 628
N. meningitides 92 (79.3%) 495 (78.8%) 0.91
S. pneumonia 22 (19.0%) 103 (16.4%) 0.50
S. agalactie (group B) 2 (1.7%) 18 (2.9%) 0.76
E. coli 0 (0%) 10 (2.9%) 0.38
L. monocytogenes 0 (0%) 2 (0.3%) 1.0
Bloodculture positive for BM causing pathogen 116 49 (42.2%) 628 300 (47.8%) 0.27
Serum leukocyte count (x10ˆ9)b 116 16.2 (9.4) 613 17.8 (10.7) 0.15
Therapy and clinical course
Dexamethasone prescribedc 110 19 (17.3%) 628 170 (27.1%) 0.029
Duration dexamethasone therapy (days)b 110 0.6 (1.5) 602 0.9 (1.8) 0.025
Mechanical ventilationc 116 14 (12.1%) 627 39 (6.2%) 0.025
Duration of hospitalization (days)b 115 12.9 (8.0) 618 14.7 (9.4) 0.046
Seizures during hospitalizationc 115 8 (7.0%) 628 64 (10.2%) 0.28
Duration of anti-epileptic therapy (days)b 112 0.6 (2.6) 610 1.4 (5.7) 0.011
Focal neurological deficitsc, d 114 7 (6.1%) 627 94 (15.0%) 0.011
(transient) ataxiac.e 115 3 (2.6%) 628 16 (2.5%) 0.97
Outcome measure
Hearing loss 116 14 (12.1%) 628 43 (6.8%) 0.052
aNumber of subjects the variable was obtained.
bMean (standard deviation).
cNumber of subjects (%).
dFocal neurological deficits are defined as cranial nerve deficits, increased or decreased reflexes of arms or legs, increased or decreased tonus of arms or legs, focal
convulsions and ataxia.
e(Transient) ataxia was defined as signs of ataxia, which lasted at least until discharge from the hospital, as documented in the medical records.
fP-value: independent sample t-test for continuous data; x2-test for nominal data, or Fisher’s Exact test if the data does not meet the criteria for x2-test.
Abbrevations: No. = number, CSF = cerebrospinal fluid.
doi:10.1371/journal.pone.0058707.t001
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importance of hearing evaluation in clinicians and the parents in
an early stage of disease.
Further, BM and subsequent morbidity is considerably more
prevalent in developing countries where adequate follow-up,
hearing tests, financial resources and support in case of auditory
deficits are scarcely available [32]. Prediction models should be
developed these countries as well and may help to select and at
least test the group that urgently needs to achieve hearing
evaluation.
This study has several strengths. This is the first model
developed and externally validated that predicts hearing loss after
BM in childhood. In the last decade, many prediction models have
been designed and presented in literature. Before implementation
in practice is possible, external validation is an essential step
[16,17,18]. However, the majority of proposed models have never
been validated [18,33]. Therefore, successful validation of our
model is an important step forward in the development of a
complete protocol for the follow-up of children who suffered from
BM.
In general, the discrimination of a prediction model is
interpreted to be fair, good or excellent when the AUC is or
0.7–0.8, 0.8–0.9 or 0.9–1.0, respectively. This model has an AUC
of 0.84 in the development cohort and an AUC of 0.78 in the
validation cohort, thus can be at least considered as fair.
Further, state of the art methodology is used and described
clearly. Therefore it may be easily to reproduce in a wide range of
future studies.
The validation cohort was constructed using the nested cohort
approach while in the development of the rule the total initial
cohort was used [6,20]. From the 1036 patients selected from the
NRLBM database, 116 were included. Most children were
excluded in the first step because approached pediatricians or
parents refused participation or because the parents could not be
contacted due to missing or incorrect address data. From the
resulting 361 children 116 were included for validation of the
hearing loss model. This nested cohort design, in which only a
subset of cases and controls are randomly selected for further
analysis, is a known and appreciated methodology that results in
more efficiency with reference to time and financial resources [21].
This stepwise construction may lead to differences in case mix
between de development cohort and the validation cohort due to
selection. The incidence of sensorineural hearing loss was 6.8% in
the development versus 12.1% in the validation cohort (p-
value = 0.052). This difference may be explained by the fact that
in the development cohort 27% of the children were not tested for
hearing loss, resulting in underestimation of the incidence [6].
Further, an increase in awareness in the period of approximately
seven years between the two studies might have resulted in
increased follow-up and incidence of hearing loss. Last, the
selection process of the nested cohort described above may also be
responsible.
Case mix differences were also found in patient characteristics
and risk factors, such as: duration of symptoms .2 days,
meningeal irritation, dexamethasone therapy, mechanical ventila-
tion, duration of anti-epileptic therapy and focal neurological
deficits. These differences could have been responsible for a
smaller spread in the risk of hearing loss (0–91% in the
development versus 2–70% in the validation cohort). This may
in turn be responsible for the small drop in discrimination of the
model in the validation cohort. Because the differences in case mix
Table 2. Distribution of children with and without hearing loss across categories of the risk score.
Children in the cohort Children with hearing loss Children without hearing loss
Risk score
Development
(n =628)
Validation
(n=116)
Development
(n =43)
Validation
(n =14)
Development
(n=585)
Validation
(n =102)
cumulative cumulative cumulative cumulative cumulative cumulative
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Score 0 236 (38) 45 (39) 0 (0) 1 (7) 236 (40) 44 (43)
Score 1–24 86 (14) 322 (51) 14 (12) 59 (51) 2 (5) 2 (5) 2 (14) 3 (21) 84 (14) 320 (55) 12 (12) 56 (55)
Score 25–36 87 (14) 409 (65) 15 (13) 74 (64) 5 (11) 7 (16) 1 (7) 4 (29) 82 (14) 402 (69) 14 (14) 70 (69)
Score 37–63 197 (31) 606 (96) 32 (27) 106 (91) 24 (56) 31 (72) 4 (29) 8 (57) 173 (30) 575 (98) 28 (27) 98 (96)
Score $64 22 (3) 628 (100) 10 (9) 116 (100) 12 (28) 43 (100) 6 (43) 14 (100) 10 (2) 585 (100) 4 (4) 102 (100)
doi:10.1371/journal.pone.0058707.t002
Table 3. Positive and negative predictive value, sensitivity and specificity for the different cut-off points of the prediction rule.
Positive predictive
value (%)
Negative predictive
value (%) Sensitivity (%) Specificity (%)
Risk score cut-off point Development Validation Development Validation Development Validation Development Validation
Score $0 6.8 12.1 100.0 100.0 0.0 0.0
Score $1 11.0 18.3 100.0 97.8 100.0 92.9 40.3 43.1
Score $25 13.4 19.3 99.4 94.9 95.3 78.6 54.7 54.9
Score $37 16.4 23.8 98.3 94.6 83.7 71.4 68.7 68.6
Score $64 54.5 60.0 94.9 92.5 27.9 42.9 98.3 96.1
doi:10.1371/journal.pone.0058707.t003
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may partly be explained by the selection processes, we must be
careful to draw conclusions from the comparison of the incidence
of hearing loss and risk factors, while some selection bias may have
occurred.
Though, for the external validation selection bias is not a major
issue: the development cohort appeared to be a representative
sample of the pediatric BM population of that time: The NRLBM
receives approximately 90% of the isolates of Dutch BM patients,
and the 628 children included where very similar compared with
the 1605 eligible children regarding, sex, age, and causative
pathogens [6].
Validation samples may differ from development samples in
predictor (patient) characteristics and in outcome frequency.
These differences may, as we discussed, also occur during the
selection of patients in the development sample and not only
depend on selection of patients in the validation sample.
Differences between samples may be caused by sampling
variability or true differences, and not by selection bias per se.
The goal of external validation is to investigate to what extend
these differences influence the generalizability of the prediction
model. Sampling variability (or working with smaller validation
samples) will often show a small influence on the performance of
the prediction model. We showed that at low and high risk score
categories, which are most important for clinical practice, the
model performed equally well in the validation as in the
development sample [16,18,34,35].
Information bias may have occurred. Risk factors and the
outcome were determined retrospectively, with a risk of bias and
missing data. To minimize the chance of bias, collection and
interpretation of clinical data from the medical files was performed
in a standardized w ay, and consensus meetings were held when
there was any doubt about how to interpret the medical files. The
diagnosis ‘‘perceptive hearing loss of .25 dB’’ is made in the
Netherlands by clinicians or audiologists by standard tests.
Multiple imputation techniques were used for substitution of
missing data, which is currently the most reliable strategy to deal
with missing information on covariates [26,36,37,38].
Further, sample size of the validation cohort was small. A
frequently used general rule in the development of clinical
prediction models is that the ratio events per variable (EVP)
should be approximately 10 [39]. In the development cohort there
were 43 events for 5 predictors included in the model, resulting in
an EVP of 8.6. For external validation new insights in sample size
issues are developed in recent years. It has been suggested that to
detect minor changes in discrimination and calibration, and
prevent type II error (the Null hypothesis of equal model
performance is falsely not rejected), the validation cohort should
contain at least 100 events and 100 non-events [40]. The sample
size of our validation cohort is limited, and therefore small
differences in calibration might have been missed.
Future Perspectives
It is hypothesized that the distribution of BM pathogens has
changed since the introduction of these vaccines and therefore the
model will not perform well in the contemporary population.
Since the development of the prediction rule two new vaccines
against N. meningitidis serogroup C and high frequency serotypes of
S. pneumoniae were introduced in the Netherlands and other
western countries: Accompanied by a spontaneous decrease of N.
meningitidis serogroup B infections this resulted in a dramatic
decrease in incidence of BM. Serotype replacement with
increasing incidence of infections has not yet occurred for N.
meningitidis, but new outbreaks with non-vaccine-serotypes are
possible and have occurred in history [41,42,43]. For S. pneumoniae
there is a net reduction of invasive infections but an increase in
infections with non-vaccine-serotypes is observed [44]. Therefore,
we should be careful expecting BM to become and stay a rare
disease, and prediction rules for sequelae remain valuable. In a
recent study our group simulated a population without the seven
serotypes of S. pneumoniae included in the vaccine, and showed that
the model remains stable in this situation [45]. To investigate
whether the long-term consequences of vaccination have impact
on the performance of the model, another validation study in
children that were infected more recently is planned.
Another important development is the rapidly increasing
knowledge on the influence of genetics on the course of diseases.
This also applies for BM and hearing loss, and in recent
publications an effort was made to disclose the influence of
genetic variation in the immune response and the course of the
disease in children. Van Well et al. described a strong association
between host genetic polymorphisms in pathogen recognition
receptors and hearing loss after BM extracted from both
development and validation cohort described in this study [46].
Additional analyses will be performed to study whether our model
can be extended with genetic factors to predict post-meningitis
hearing loss even more accurately.
We conclude that we created and externally validated a clinical
useful tool in addition to regular auditory testing for the
identification of children at high risk for hearing loss after BM.
In the future larger development and validation studies must be
performed, in which hearing loss is measured prospectively and
genetic risk factors are included in the construction of the
prediction model. In our opinion, international cooperation is
the answer to the problem of decreasing incidence in the
development of prediction models.
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